Biological E Partners with Recbio to Bring HPV9 Vaccine to India and Global Markets

Biological E, an Indian pharmaceutical manufacturer, has partnered with China’s Recbio to produce and commercialize the REC603 HPV9 vaccine, marking a significant step in combating HPV-related cancers. Designed to protect against nine strains of Human Papillomavirus (HPV), the vaccine targets cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts. Globally, HPV infections are linked to 620,000 cancer cases in women and 70,000 in men annually.

Under the agreement, Recbio will supply drug substances and transfer technology for formulation, filling, and packaging to Biological E. This collaboration also grants Biological E access to global tender markets, including UNICEF and the Pan American Health Organization (PAHO).

Recbio’s REC603 is currently undergoing Phase III clinical trials in China and is designed for individuals aged 9 to 45. Large-scale manufacturing by Biological E in India will begin after the technology transfer, ensuring affordable doses for both domestic and international markets.

Dr. Liu Yong, CEO of Recbio, stated, “This partnership accelerates the global availability of the HPV9 vaccine, addressing the growing demand for more affordable cervical cancer prevention solutions.”

This agreement positions Recbio for international expansion while leveraging Biological E’s manufacturing expertise to improve vaccine accessibility worldwide.